Sutro Biopharma price target raised to $41 from $35 at Citizens

Citizens raised the firm’s price target on Sutro Biopharma (STRO) to $41 from $35 and keeps an Outperform rating on the shares. Recent AACR presentations highlighted strong preclinical results across Sutro’s pipeline, including data suggesting its lead program STRO-004 may outperform existing therapies and promising durability from a partnered candidate, the analyst tells investors in a research note. With advancing clinical progress, potential best-in-class data by mid-2026, and solid cash reserves, the company is viewed as undervalued despite a sharp year-to-date rally, the firm says.